PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
02-Nov-2022 Meet CD Genomics at the SITC 37th Annual Meeting CD Genomics
02-Nov-2022 Cellbag Bioreactor Chambers Market 2022 Outlook, Current and Future Industry Landscape Analysis 2027 MARKITWIRED
02-Nov-2022 Bioelectric Medicine Market is expected to grow at a CAGR of Approximately Over 2022-2027 MARKITWIRED
02-Nov-2022 Alternatives For Injectable Diabetes Care Market 2022 Outlook, Current and Future Industry Landscape Analysis 2026 MARKITWIRED
02-Nov-2022 Evotec presents paradigm shift in biologics at Capital Markets Day Evotec SE
02-Nov-2022 Medical Device Analytical Testing Outsourcing Market To Generate $10,904.8 Million by 2030 P&S Intelligence
02-Nov-2022 Next-Generation Antibody Therapeutics Market Growth, Share, Demand Analysis of Key Players P&S Intelligence
02-Nov-2022 Straumann Group reports 12% organic revenue growth in the third quarter of 2022 Straumann Holding AG
02-Nov-2022 Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules Kuros Biosciences AG
02-Nov-2022 Samenvatting: Noramco kondigt indiening en reactivering aan van het geneesmiddelen master dossier voor actief farmaceutisch ingrediënt methylnaltrexon bromide Businesswire
02-Nov-2022 Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round Legend Capital
02-Nov-2022 Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round Legend Capital
02-Nov-2022 CD Formulation Releases Nanoparticle Development Services for Drug Delivery System Research CD Formulation
02-Nov-2022 Alfa Chemistry: Pretreatment Chemicals Make Electroplating More Efficient Alfa Chemistry
02-Nov-2022 Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines Businesswire
02-Nov-2022 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors Businesswire
01-Nov-2022 Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα Businesswire
01-Nov-2022 Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan Businesswire
01-Nov-2022 Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update Businesswire
01-Nov-2022 Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer Businesswire